绥美凯是在什么时候上市的？

(Dolutegravir) is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment regimen of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine.

When was Suimeikai launched on the market?

Suimeikai (dolute abalamib tablets) was approved by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, the first complete antiviral treatment drug with dolutegravir (also known as DTG in English) as the core, dolutegravir tablets, was officially launched in China. This is also the first complete single-pill compound treatment plan in the field of HIV treatment in China.

Dolutegravir tablets are composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs.

Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating.

In 2016, GSK announced the launch of the integrase DTG (Tevicai) in China. This therapeutic agent has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time (Doteta abalamib tablets) is a core drug with DTG, an integrase inhibitor, and a treatment plan with two backbone drugs, abacavir and lamivudine, and is made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.